BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20861673)

  • 1. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.
    Phaeton R; Harris M; Jiang Z; Wang XG; Einstein MH; Goldberg GL; Casadevall A; Dadachova E
    Cancer Biol Ther; 2010 Nov; 10(10):1041-7. PubMed ID: 20861673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
    Phaeton R; Wang XG; Einstein MH; Goldberg GL; Casadevall A; Dadachova E
    Cancer; 2010 Feb; 116(4 Suppl):1067-74. PubMed ID: 20127955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
    Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein.
    Harris M; Wang XG; Jiang Z; Phaeton R; Koba W; Goldberg GL; Casadevall A; Dadachova E
    Br J Cancer; 2013 Mar; 108(4):859-65. PubMed ID: 23385729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
    Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
    Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
    Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
    Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel intracellular nanobody against HPV16 E6 oncoprotein.
    Zhang W; Shan H; Jiang K; Huang W; Li S
    Clin Immunol; 2021 Apr; 225():108684. PubMed ID: 33549834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
    Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
    Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcellular localization and quantitation of the human papillomavirus type 16 E6 oncoprotein through immunocytochemistry detection.
    Jackson R; Togtema M; Zehbe I
    Virology; 2013 Jan; 435(2):425-32. PubMed ID: 23084288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
    Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
    Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma.
    Madrigal M; Janicek MF; Sevin BU; Perras J; Estape R; Peñalver M; Averette HE
    Gynecol Oncol; 1997 Jan; 64(1):18-25. PubMed ID: 8995542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E6/E7 oncoproteins of high risk HPV-16 upregulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells.
    Zhu D; Ye M; Zhang W
    Int J Clin Exp Pathol; 2015; 8(5):4981-9. PubMed ID: 26191191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
    Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
    Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.
    Cheng YX; Chen GT; Yang X; Wang YQ; Hong L
    Curr Med Sci; 2018 Apr; 38(2):212-221. PubMed ID: 30074178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.
    Le Poole IC; ElMasri WM; Denman CJ; Kroll TM; Bommiasamy H; Lyons Eiben G; Kast WM
    Cancer Immunol Immunother; 2008 Jun; 57(6):789-97. PubMed ID: 18004565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
    Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
    McFarlane M; MacDonald AI; Stevenson A; Graham SV
    J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.